Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Targeted mutation of the DNA methyltransferase gene results in embryonic lethality

Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984 · see citing works

Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells

Thomas, K. R., & Capecchi, M. R. (1987) · Cell · doi:10.1016/0092-8674(87)90646-5 · Cited by 2,355 · see citing works

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · see citing works

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · see citing works

Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes

Mansour, S. L., Thomas, K. R., & Capecchi, M. R. (1988) · Nature · doi:10.1038/336348a0 · Cited by 1,683 · see citing works

The B7 and CD28 receptor families

June, C. H., Bluestone, J. A., Nadler, L. M., & Thompson, C. B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90080-9 · Cited by 1,296 · see citing works

Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg

Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., MONTAG, A. G., Brady, W., Gibson, M. G., Linsley, P. S., & Bluestone, J. A. (1992) · Science · doi:10.1126/science.1323143 · Cited by 1,121 · see citing works

β2-Microglobulin deficient mice lack CD4−8+ cytolytic T cells

Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., & Jaenisch, R. (1990) · Nature · doi:10.1038/344742a0 · Cited by 1,014 · see citing works

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 977 · see citing works

B70 antigen is a second ligand for CTLA-4 and CD28

Azuma, M., Ito, D., Yagita∥, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 910 · see citing works

Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation

Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Lombard, L. A., Gray, G. S., & Nadler, L. M. (1993) · Science · doi:10.1126/science.7694363 · Cited by 903 · see citing works

Treatment of Murine Lupus with CTLA4Ig

Finck, B. K., Linsley, P. S., & Wofsy, D. (1994) · Science · doi:10.1126/science.7520604 · Cited by 667 · see citing works

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.

Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasetti, C., & Damle, N. K. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.6.1595 · Cited by 581 · see citing works

T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.

Turka, L. A., Linsley, P. S., Lin, H., Brady, W., Leiden, J. M., Wei, R. Q., Gibson, M. L., Zheng, X. G., Myrdal, S. E., & Gordon, D. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.11102 · Cited by 533 · see citing works

CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location

Harper, K., Balzano, C., Rouvier, É., Mattéi, M., Luciani, M., & Golstein, P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.3.1037 · Cited by 432 · see citing works

Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice

Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Hathcock, K. S., László, G., McKnight, A. J., Kim, J., Du, L., Lombard, D. B., et al. (1993) · Science · doi:10.1126/science.7694362 · Cited by 359 · see citing works

Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.

Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J. W., Kim, J., Goldberg, J. M., Hathcock, K. S., & László, G. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.6.2185 · Cited by 351 · see citing works

Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4

Kearney, E. R., Walunas, T. L., Karr, R. W., Morton, P. A., Loh, D. Y., Bluestone, J. A., & Jenkins, M. K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1032 · Cited by 312 · see citing works

Expression and functional significance of an additional ligand for CTLA-4.

Lenschow, D. J., Su, G. H., Zuckerman, L. A., Nabavi, N., Jellis, C. L., Gray, G. S., Miller, J., & Bluestone, J. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11054 · Cited by 259 · see citing works

Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.

Peach, R., Bajorath, J., Brady, W., Leytze, G., Greene, J. L., Naemura, J. R., & Linsley, P. S. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.6.2049 · Cited by 248 · see citing works

The mouse Pgk-1 gene promoter contains an upstream activator sequence

McBurney, M. W., Sutherland, L. C., Adra, C. N., Leclair, B., Rudnicki, M. A., & Jardine, K. E. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5755 · Cited by 193 · see citing works

CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells.

Schneider, H. E., Prasad, K. V., Shoelson, S. E., & Rudd, C. E. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.1.351 · Cited by 165 · see citing works

Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.

Cross, A. H., Girard, T. J., Giacoletto, K. S., Evans, R. J., Keeling, R. M., Lin, R. F., Trotter, J. L., & Karr, R. W. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117982 · Cited by 155 · see citing works

CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production

Freeman, G. J., Lombard, D. B., Gimmi, C. D., Brod, S. A., Lee, K., Laning, J. C., Hafler, D. A., Dorf, M. E., Gray, G. S., & Reiser, H. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.12.3795 · Cited by 150 · see citing works

Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.

Perrin, P. J., Scott, D. E., Quigley, L., Albert, P. S., Feder, O., Gray, G. S., Abe, R., June, C. H., & Racke, M. K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.1481 · Cited by 146 · see citing works

Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance

Boussiotis, V. A., Gribben, J. G., Freeman, G. J., et al. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90087-6 · Cited by 135 · see citing works

A negative regulatory function of B7 revealed in B7-1 transgenic mice

Sethna, M. P., van Perijs, L., Sharpe, A. H., Abbas, A. K., & Freemant, G. J. (1994) · Immunity · doi:10.1016/1074-7613(94)90072-8 · Cited by 78 · see citing works

Medullary thymic epithelium expresses a ligand for CTLA4 in situ and in vitro.

Nelson, A. J., Hosier, S., Brady, W., et al. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2453 · Cited by 64 · see citing works

Induction of focal spongiform neurodegeneration in developmentally resistant mice by implantation of murine retrovirus-infected microglia

Lynch, W. P., Robertson, S. J., & Portis, J. L. (1995) · Journal of Virology · doi:10.1128/jvi.69.3.1408-1419.1995 · Cited by 45 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Cancer immunotherapy comes of age

Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · see citing works

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works

Lymphocyte Homing and Homeostasis

Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

Points of control in inflammation

Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · see citing works

CD28/B7 SYSTEM OF T CELL COSTIMULATION

Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · see citing works

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189 · see citing works

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · see citing works

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · see citing works

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · see citing works

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · see citing works

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648 · see citing works

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482 · see citing works

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · see citing works

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233 · see citing works

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · see citing works

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115 · see citing works

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · see citing works

TIM3 comes of age as an inhibitory receptor

Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959 · see citing works

CD28 Costimulation: From Mechanism to Therapy

Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · see citing works

Immune-checkpoint inhibitors: long-term implications of toxicity

Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982 · see citing works

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · see citing works

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · see citing works

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898 · see citing works

Tim‐3 and its role in regulating anti‐tumor immunity

Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856 · see citing works

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · see citing works

Single-cell eQTL mapping identifies cell type–specific genetic control of autoimmune disease

Yazar, S., Alquicira-Hernandez, J., Wing, K., Senabouth, A., Gordon, M. G., Andersen, S., Lu, Q., Rowson, A., Taylor, T. R. P., Clarke, L., et al. (2022) · Science · doi:10.1126/science.abf3041 · Cited by 682 · see citing works

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · see citing works

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · see citing works

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · see citing works

Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors

Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590 · see citing works

The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses

Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576 · see citing works

Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4

Marengère, L. E. M., Waterhouse, P., Duncan, G. S., Mittrücker, H.-W., Feng, G.-S., & Mak, T. W. (1996) · Science · doi:10.1126/science.272.5265.1170 · Cited by 551 · see citing works

CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics

van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., & Davis, S. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.393 · Cited by 551 · see citing works

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511 · see citing works

Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma

Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459 · see citing works

Role of the PD-1 pathway in the immune response

Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444 · see citing works

Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo

Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434 · see citing works

CTLA-4 regulates induction of anergy in vivo

Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K., & Sharpe, A. H. (2001) · Immunity · doi:10.1016/s1074-7613(01)00097-8 · Cited by 428 · see citing works

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383 · see citing works

Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.

Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392 · see citing works

T Cell Exhaustion

Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420 · see citing works

Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family

Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391 · see citing works

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade

Nakamoto, N., Cho, H., Shaked, A., Olthoff, K., Valiga, M. E., Kaminski, M., Gostick, E., Price, D. A., Freeman, G. J., Wherry, E. J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000313 · Cited by 380 · see citing works

Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses

Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374 · see citing works

A peripheral circulating compartment of natural naive CD4 Tregs

Valmori, D., Merlo, A., Souleimanian, N. E., Hesdorffer, C. S., & Ayyoub, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23963 · Cited by 319 · see citing works

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290 · see citing works

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

Maruhashi, T., Okazaki, I.-M., Sugiura, D., Takahashi, S., Maeda, T. K., Shimizu, K., & Okazaki, T. (2018) · Nature Immunology · doi:10.1038/s41590-018-0217-9 · Cited by 275 · see citing works

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278 · see citing works

Structural Analysis of CTLA-4 Function In Vivo

Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L., & Thompson, C. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5319 · Cited by 252 · see citing works

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236 · see citing works

Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms

Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237 · see citing works

Mice Lacking the Orphan G Protein-Coupled Receptor G2A Develop a Late-Onset Autoimmune Syndrome

Le, L. Q., Kabarowski, J. H. S., Weng, Z., Satterthwaite, A. B., Harvill, E. T., Jensen, E. R., Miller, J. F., & Witte, O. N. (2001) · Immunity · doi:10.1016/s1074-7613(01)00145-5 · Cited by 215 · see citing works

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1467-x · Cited by 201 · see citing works

Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies

Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186 · see citing works

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0328-8 · Cited by 190 · see citing works

CTLA-4 trafficking and surface expression

Valk, E., Rudd, C. E., & Schneider, H. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.011 · Cited by 177 · see citing works

Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors

Cramer, P., & Bresalier, R. S. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0540-6 · Cited by 167 · see citing works

Control of Autoimmune Myocarditis and Multiorgan Inflammation by Glucocorticoid-Induced TNF Receptor Family-Related Proteinhigh, Foxp3-Expressing CD25+ and CD25− Regulatory T Cells

Ono, M., Shimizu, J., Miyachi, Y., & Sakaguchi, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4748 · Cited by 162 · see citing works

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157 · see citing works

<p>Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor</p>

Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153 · see citing works

CD28: a signalling perspective

WARD, S. G. (1996) · Biochemical Journal · doi:10.1042/bj3180361 · Cited by 149 · see citing works

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137 · see citing works

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

Du, X., Liu, M., Su, J., Zhang, P., Tang, F., Ye, P., Devenport, M., Wang, X., Zhang, Y., Liu, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0012-z · Cited by 123 · see citing works

Regulation of Cytotoxic T Lymphocyte-Associated Molecule-4 by Src Kinases

Chuang, E., Lee, K.-M., Robbins, M. D., Duerr, J. M., Alegre, M.-L., Hambor, J. E., Neveu, M. J., Bluestone, J. A., & Thompson, C. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1270 · Cited by 119 · see citing works

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P. (2016) · Nature Communications · doi:10.1038/ncomms12335 · Cited by 111 · see citing works

CTLA‐4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization

Schneider, H., Smith, X., Liu, H., Bismuth, G., & Rudd, C. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737423 · Cited by 116 · see citing works

Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management

Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100 · see citing works

Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) <u>Restricts</u> Clonal Expansion of Helper T Cells

Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102 · see citing works

Mechanisms of immune checkpoint inhibitor-mediated liver injury

Shojaie, L., Ali, M., Iorga, A., & Dara, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.003 · Cited by 98 · see citing works

Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma

Huang, P.-Y., Guo, S.-S., Zhang, Y., Lu, J.-B., Chen, Q.-Y., Tang, L.-Q., Zhang, L., Liu, L.-T., Zhang, L., & Mai, H.-Q. (2016) · Oncotarget · doi:10.18632/oncotarget.7421 · Cited by 96 · see citing works

Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states

Wei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97 · see citing works

CTLA-4 Ligation Suppresses CD28-induced NF-κB and AP-1 Activity in Mouse T Cell Blasts

Olsson, C., Riebeck, K., Dohlsten, M., & Michaëlsson, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14400 · Cited by 84 · see citing works

T Cell Receptor-Interacting Molecule Acts as a Chaperone to Modulate Surface Expression of the CTLA-4 Coreceptor

Valk, E., Leung, R., Kang, H., Kaneko, K., Rudd, C. E., & Schneider, H. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.024 · Cited by 78 · see citing works

Tyrosine Phosphatase SHP-2 Binding to CTLA-4: Absence of Direct YVKM/YFIP Motif Recognition

Schneider, H., & Rudd, C. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2234 · Cited by 78 · see citing works

The effects of age and systemic metabolism on anti-tumor T cell responses

Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69 · see citing works

Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue

Aguirre, L. E., Guzman, M. E., Lopes, G., & Hurley, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0195 · Cited by 68 · see citing works

Src Family Tyrosine Kinases Associate with and Phosphorylate CTLA-4 (CD152)

Miyatake, S., Nakaseko, C., Umemori, H., Yamamoto, T., & Saito, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9191 · Cited by 65 · see citing works

Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58 · see citing works

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55 · see citing works

Autoimmune Myocarditis, Old Dogs and New Tricks.

Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51 · see citing works

CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch

Hoff, H., Kolar, P., Ambach, A., Radbruch, A., & Brunner-Weinzierl, M. C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.03.017 · Cited by 39 · see citing works

Overcoming immunological tolerance to melanoma: targeting CTLA-4

HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36 · see citing works

Learning from the nexus of autoimmunity and cancer

Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33 · see citing works

Immunotherapy Resistance in Glioblastoma

Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34 · see citing works

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease

Seethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15 · see citing works

Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s

DeRenzo, C., & Gottschalk, S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_10 · Cited by 12 · see citing works

Regulation of CD28 expression on CD8+ T cells by CTLA-4

Berg, M., & Zavazava, N. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0107065 · Cited by 29 · see citing works

Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease Progression

Kosmaczewska, A., Boćko, D., Ciszak, L., Włodarska−Polińska, I., Kornafel, J. A., Szteblich, A., Masternak, A., & Frydecka, I. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9471-y · Cited by 38 · see citing works

CD28-independent Costimulation of T Cells in Alloimmune Responses

Yamada, A., Kishimoto, K., Dong, V. M., Sho, M., Salama, A. D., Anosova, N. G., Bénichou, G., Mandelbrot, D. A., Sharpe, A. H., Turka, L. A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.140 · Cited by 114 · see citing works

Cutting Edge: Cbl-b: One of the Key Molecules Tuning CD28- and CTLA-4-Mediated T Cell Costimulation

Li, D., Gál, I., Vermes, C., Alegre, M., Chong, A. S., Chen, L., Shao, Q., Adarichev, V. A., Xu, X., Koreny, T., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7135 · Cited by 118 · see citing works

CD28-Dependent CTLA-4 Expression Fine-Tunes the Activation of Human Th17 Cells

Krummey, S. M., Hartigan, C. R., Liu, D., & Ford, M. L. (2020) · iScience · doi:10.1016/j.isci.2020.100912 · Cited by 9 · see citing works